Journal
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fcimb.2019.00147
Keywords
Zika virus; dengue virus (DENV); DNA vaccine; PrM/E proteins; cross-reactive immune responses; Zika-DNA-vaccination Confers Cross-protection to DENVs
Categories
Funding
- National Natural Science Foundation of China [81471957, 81772172, 81372935, 81671971, U1602223]
Ask authors/readers for more resources
Both Zika virus (ZIKV) and four serotypes of dengue virus (DENV1-4) are antigenically related mosquito-borne flaviviruses that co-circulate in overlapping geographic distributions. The considerable amino acid sequence homology and structural similarities between ZIKV and DENV1-4 may be responsible for the complicated immunological cross-reactivity observed for these viruses. Thus, a successful Zika vaccine needs to not only confer protection from ZIKV infection but must also be safe during secondary exposures with other flavivirus, especially DENVs. In this study, we used a Zika DNA vaccine candidate (pV-ZME) expressing the ZIKV premembrane and envelop proteins to immunize BALB/c mice and evaluated the potential cross-reactive immune responses to DENV1-4. We observed that three doses of the pV-ZME vaccine elicited the production of cross-reactive antibodies, cytokines and CD8(+) T cell responses and generated cross-protection against DENV1-4. Our results demonstrate a novel approach for design and development of safe Zika and/or dengue vaccines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available